Overview :
DCGI granted market authorisation to QDENGA (TAK-003), India's first dengue vaccine. Developed by Takeda, it protects against all four dengue serotypes. The vaccine is for individuals aged 4 to 60 years. It requires two doses given three months apart. No pre-vaccination screening is needed.
What Is QDENGA (TAK-003)?
QDENGA is a dengue vaccine. It is a live-attenuated vaccine. This means it contains a weakened form of the virus. It cannot cause the disease. But it triggers the immune system to build protection.
The vaccine is tetravalent. This is a crucial feature. Dengue has four different virus serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. A person can get infected multiple times. Each infection is with a different serotype. QDENGA provides protection against all four. This is a major advantage.
Who Can Take It?
The vaccine is approved for a wide age group. It is for individuals aged 4 to 60 years. This covers children, adolescents, and adults. The vaccine does not require pre-vaccination screening. You don't need to test if you have had dengue before. It can be given irrespective of previous infection.
How Is It Administered?
QDENGA follows a two-dose regimen. You take the first dose. Then you wait three months. Then you take the second dose. This schedule ensures optimal immune response.
What Is Dengue?
Dengue is a mosquito-borne tropical disease. The dengue virus causes it. Most people experience mild, flu-like symptoms. These include fever, headache, and joint pain.
But a small number of patients develop severe disease. This can lead to potentially fatal bleeding and organ damage. This is called severe dengue or dengue hemorrhagic fever. It is a medical emergency.
Dengue poses a significant global public health threat. It is prevalent in over 125 countries. India bears a heavy burden. The country accounts for nearly one-third of the global dengue cases.
Global Approval
QDENGA is not new to the world. It has already been approved in more than 40 countries. These include the European Union, the United Kingdom, Brazil, Indonesia, and Argentina. Now India joins this list. This is a significant step in combating dengue in the country.
Analogy: A Security Guard Team for Your Body
Imagine your body is a building. Dengue viruses are four different types of intruders. They look similar but have different disguises. The first time, you don't have security. The intruders get in. You get sick.
QDENGA is like hiring a security guard team. The team is trained to recognise all four intruder types. They are given a description of each. They are ready to stop any of them.
The two doses are like training sessions. The first session introduces the guards to the intruders. The second session reinforces their training. Now they are fully prepared. They can protect your building from any dengue attack.
Why This Matters for Exams
This news is relevant for:
-
Science and Technology: Vaccines, immunology, dengue virus.
-
Public Health: Disease prevention, government approvals.
-
Current Affairs: Important for UPSC and state exams.
-
Pharma: Drug approvals, global pharmaceutical companies.
Exam-Focused Points :
-
Vaccine Name: QDENGA (TAK-003).
-
Developer: Japanese pharmaceutical company Takeda.
-
Approval: First dengue vaccine approved in India by DCGI.
-
Type: Live-attenuated tetravalent vaccine.
-
Target: Protects against all four dengue serotypes (DENV-1 to DENV-4).
-
Dosage: Two doses, three months apart.
-
Age Group: Approved for individuals aged 4 to 60 years.
FAQs :
Q1: What is QDENGA?
Ans: India's first approved dengue vaccine, developed by Takeda.
Q2: How many dengue serotypes does QDENGA protect against?
Ans: All four serotypes (DENV-1 to DENV-4).
Q3: Who can take the QDENGA vaccine?
Ans: Individuals aged 4 to 60 years.
Q4: How many doses of QDENGA are required?
Ans: Two doses, given three months apart.
Q5: Do I need pre-vaccination screening before taking QDENGA?
Ans: No, screening is not required.